356,529 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, HoldingsChannel.com reports. The fund acquired 356,529 shares of the biopharmaceutical company’s stock, valued at approximately $162,577,000.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock valued at $4,336,064,000 after acquiring an additional 240,534 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock worth $779,857,000 after buying an additional 75,936 shares during the last quarter. Orbis Allan Gray Ltd lifted its position in shares of Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after buying an additional 486,489 shares during the last quarter. Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $662,837,000. Finally, American Century Companies Inc. grew its position in shares of Alnylam Pharmaceuticals by 1.9% in the 2nd quarter. American Century Companies Inc. now owns 1,793,846 shares of the biopharmaceutical company’s stock valued at $584,957,000 after buying an additional 33,411 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $359.27 on Tuesday. The company has a 50-day simple moving average of $417.09 and a 200-day simple moving average of $422.89. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45. The company has a market capitalization of $47.46 billion, a PE ratio of 1,496.96 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55.

Analyst Upgrades and Downgrades

ALNY has been the subject of several research reports. Piper Sandler reissued an “overweight” rating and issued a $489.00 target price (up from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 10th. Raymond James Financial reiterated an “outperform” rating and set a $472.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, January 12th. Bank of America reduced their target price on shares of Alnylam Pharmaceuticals from $530.00 to $529.00 and set a “buy” rating for the company in a report on Monday, January 12th. Finally, Leerink Partners lowered their price target on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a report on Monday, December 15th. Twenty-two research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $490.96.

Insider Buying and Selling

In related news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, November 17th. The stock was sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the completion of the transaction, the executive vice president directly owned 21,264 shares of the company’s stock, valued at approximately $9,615,155.52. The trade was a 36.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Yvonne Greenstreet sold 15,650 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $453.69, for a total value of $7,100,248.50. Following the completion of the sale, the chief executive officer directly owned 65,409 shares in the company, valued at $29,675,409.21. This trade represents a 19.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 56,955 shares of company stock valued at $24,072,733 in the last 90 days. 1.20% of the stock is owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.